You just read:

IDEV's Pivotal SUPERB Trial Demonstrates SUPERA® Stent Significantly Exceeds VIVA Criteria for One-Year Patency in Femoropopliteal Artery Disease

News provided by

IDEV Technologies, Inc.

11 Oct, 2012, 01:00 BST